Antibodies directed against nerve growth factor inhibit the acute bronchoconstriction due to allergen challenge in guinea-pigs
Article first published online: 8 APR 2002
Clinical & Experimental Allergy
Volume 32, Issue 2, pages 325–328, February 2002
How to Cite
De Vries, A., Engels, F., Henricks, P. A. J., Leusink-Muis, T., Fischer, A. and Nijkamp, F. P. (2002), Antibodies directed against nerve growth factor inhibit the acute bronchoconstriction due to allergen challenge in guinea-pigs. Clinical & Experimental Allergy, 32: 325–328. doi: 10.1046/j.1365-2222.2002.01283.x
- Issue published online: 8 APR 2002
- Article first published online: 8 APR 2002
- Submitted 15 December 2000; revised 15 August 2001; accepted 29 August 2001
We have previously demonstrated that the administration of nerve growth factor (NGF) to guinea-pigs results in airway hyper-responsiveness within 1 h.
Objective In the present study we document the involvement of NGF in the acute allergic airway response.
Methods Guinea-pigs that are sensitized to ovalbumin show an acute bronchoconstriction directly after challenge with ovalbumin.
Results Intratracheal application of 10 µg of antibodies directed against NGF (anti-NGF) 1 h before the challenge reduces the acute severe bronchoconstriction to approximately 40% and the sustained bronchoconstriction to approximately 20% of the reaction in controls. This shows a high potency of anti-NGF in diminishing the direct bronchoconstriction. Inhibition of the tyrosine kinases of the tyrosine kinase receptor A, the high-affinity receptor for NGF, has no effect on the bronchoconstriction. Therefore, we postulate that the p75, the low-affinity receptor for neurotrophins, is responsible for the acute bronchoconstriction. Our findings suggest a role for NGF in the induction of the acute asthmatic reaction.
Conclusion These findings offer a new potential therapeutic strategy for the treatment of allergic asthma.